Last deal

$460M

Amount

Post-IPO Equity

Stage

26.10.2020

Date

3

all rounds

$1.18B

Total amount

date founded

Financing round

General

About Company
Turning Point Therapeutics is developing investigational drugs to overcome limitations of existing cancer therapies.

Industry

Sector :

Subsector :

Keywords :

Also Known As

TP Therapeutics, Turning Point Tx

founded date

08.10.2013

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. It has shown promising results in both kinase-naïve and pre-treated patients and is expected to enter a registrational study in the second half of 2019. Turning Point Therapeutics aims to develop therapies that make a significant impact in cancer treatment.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Enliven Therapeutics

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boulder, CO, USA

total rounds

5

total raised

$395M
Sorrento Therapeutics

Sorrento Therapeutics

Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

8

total raised

$264.42M

count Of Investments

5

count Of Exists

1
Cend Therapeutics Inc.

Cend Therapeutics Inc.

Cend Therapeutics Inc. develops cancer therapies that overcome drug delivery barriers to solid tumors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

La Jolla, San Diego, CA, USA

total rounds

2

total raised

$3.1M
Ziopharm oncology

Ziopharm oncology

ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

New York, NY, USA

total rounds

9

total raised

$293.39M
M&A Details
1

Acquired by

Bristol Myers Squibb

announced date

03.06.2022

price

$4.1B

Financials

Funding Rounds
8
3

Number of Funding Rounds

$1.18B

Money Raised

Their latest funding was raised on 26.10.2020. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
26.10.2020
$460M
18.05.2020
$373.8M
16.09.2019
$202.5M
Co-Investors
Investors
11
4

Number of lead investors

11

Number of investors

Investor 
Lead 
Round 
Partners 
No
Private Equity
No
Private Equity
No
Private Equity
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
SR One

SR One

SR One Capital Management is a biotech venture capital firm.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Cambridge, MA, USA

count Of Investments

158

count Of Exists

36
Nextech Invest

Nextech Invest

Nextech Invest is a venture capital and private equity firm that focuses on precision therapies in oncology.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Biotechnology

Location

Zürich, Switzerland

count Of Investments

78

count Of Exists

8

People

Founders
2
Y. Peter Li
Y. Peter Li

Y. Peter Li

current job

BlossomHill Therapeutics
BlossomHill Therapeutics

organization founded

2

Y. Peter Li

J. Jean Cui
J. Jean Cui

J. Jean Cui

J. Jean Cui, Ph.D. is a renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at Big Pharma and biotech companies (Pfizer, Pharmacia/SUGEN, etc.). Jean is the lead inventor of Pfizer’s precision oncology medicine, crizotinib, brand named XALKORI®. She created the drug’s novel chemical scaffold based on co-crystal structure and designed the final clinical compound crizotinib. XALKORI® was fast track approved by US Food and Drug Administration on August 26, 2011 for ALK positive late stage non-small cell lung cancer (NSCLC). In addition to the invention of crizotinib, Jean worked on several other oncology projects, including SUTENT®. She also created the clinical c-MET specific inhibitor PF-04217903 and designed the ALK second generation clinical compound PF-06463922. Her exceptional achievements in drug discovery and development have earned her many prestigious awards which include: the 38th National Inventor of the Year by Intellectual Property Owners’ Association (2011); Woman Worth Watching by Diversity Journal (2012); American Chemical Society Hero of Chemistry (2013); Pfizer Worldwide R&D Achievement Awards (2006 and 2012); Pfizer Innovation Award (2011); CABS K. Fong Award for Life Sciences (2013). Her story of crizotinib invention was featured in a Wall Street Journal article titled “Drug Discovery Gets an Upgrade” on April 16, 2012.

current job

Turning Point Therapeutics
Turning Point Therapeutics

organization founded

2

J. Jean Cui

Employee Profiles
12
Steve Sabus

Steve Sabus

Chief Commercial Officer

Adam D. Levy

Adam D. Levy

Senior Vice President, Investor Relations and Corporate Communications

Kumar Srinivasan

Kumar Srinivasan

Executive Vice President & CBO

Siegfried Reich

Siegfried Reich

Executive Vice President, CSO

J. Jean Cui

J. Jean Cui

Scientific Founder & Board Member

Homa Yeganegi

Homa Yeganegi

Senior Vice President, Project Team Leader and Head of Medical Affairs

Athena Countouriotis

Athena Countouriotis

President and Chief Executive Officer

Jeffrey P. Whitten

Jeffrey P. Whitten

Vice President of Pre-Clinical Development

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month